• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/23/25 5:00:33 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email
    false 0001655923 A1 00-0000000 0001655923 2025-06-19 2025-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 19, 2025

     

    Alpha Cognition Inc.

    (Exact name of registrant as specified in its charter)

     

    British Columbia   001-42403   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    1452 Hughes Rd., Ste 200
    Grapevine, Texas
      76051
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: 604-564-9244

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol   Name of each exchange on which registered:
    Common Shares, no par value   ACOG   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 19, 2025, at the annual meeting of stockholders of Alpha Cognition Inc. (the “Company”), the stockholders approved the adoption of the new 2025 Stock Incentive Plan (the “2025 Stock Incentive Plan”). The 2025 Stock Incentive Plan authorizes the compensation committee of the Board or such other committee designated by the Board to administer the 2025 Stock Incentive Plan to provide equity based compensation in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalents, or other stock-based awards. A more detailed description of the 2025 Stock Incentive Plan is contained in the Company’s definitive proxy statement of Schedule 14A as filed with the Commission on April 30, 2025 under the heading “5. Adoption of the Company’s 2025 Stock and Incentive Plan”, which description of the 2025 Stock Incentive Plan is incorporated herein by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    The Company held its 2025 annual meeting of stockholders on June 19, 2025 (the “Meeting”). The Meeting was held in person at the Company’s principal executive offices located at 1452 Hughes Rd., Ste. 200, Grapevine, Texas 76051.

     

    As of the record date, April 22, 2025, there were a total of 16,019,787 shares of common stock issued and outstanding, no restricted shares of common stock issued and outstanding, and 316,655 preferred shares of common stock issued and outstanding and entitled to vote at the Meeting. At the Meeting, 8,404,660 shares of common stock and preferred shares of common stock were represented in person or by proxy; therefore, a quorum was present. The final voting results for the matters submitted to a vote of stockholders were as follows:

     

    Proposal No. 1 – Number of Directors

     

    To set the number of directors that constitutes the board of directors (the “Board”) of the Company at six directors:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     8,401,064    837    2,759    0 

     

    Proposal No. 2 - Election of Directors

     

    To elect the following nominees to serve as members of the Company’s Board:

     

    Nominee Name  Votes For   Votes Withheld   Broker Non Votes 
    Michael McFadden   4,338,110    66    4,066,484 
    Kenneth Cawkell   4,329,020    9,156    4,066,484 
    Rajeev ‘Rob’ Bakshi   4,338,108    68    4,066,484 
    Len Mertz   4,328,740    9,436    4,066,484 
    Phillip Mertz   4,329,020    9,156    4,066,484 
    Robert Wills   4,329,020    9,156    4,066,484 

     

    Proposal No. 3 - Ratification of Independent Registered Public Accounting Firm

     

    To ratify Manning Elliot LLP as the Company’s independent registered public accounting firm for the fiscal year ending on December 31, 2025:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     8,402,007    210    2,443    0 

     

    1

     

     

    Proposal No. 4 – Adoption of 2025 Stock Incentive Plan Proposal

     

    To approve, ratify and confirm the Company’s 2025 Stock and Incentive Plan:

     

    Votes For   Votes Against   Abstentions   Broker Non Votes 
     3,858,186    444,702    35,288    4,066,484 

     

    At the Meeting, the number of directors was set to six (6), all nominees for director were elected to office, the ratification of the independent registered public accounting firm was approved and the adoption of the 2025 Stock Incentive Plan was approved.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The following Exhibits are furnished as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ALPHA COGNITION INC.
       
      By: /s/ Michael McFadden
        Michael McFadden
        Chief Executive Officer
    Dated: June 23, 2025  

     

     

    3

     
    Get the next $ACOG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations: Bioequivalence of ZUNVEYL, a Galantamine Prodrug to Galantamine Hydrobromide Extended-Release Demonstrated Under Steady State Conditions (Poster #107147) - July 27 Bioequivalence of ZUNVEYL, a Galantamine Prodrug to Galantamine Hydrobromide Immediate-Release Demonstrated Under

      7/8/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families. Additionally, a history of mTBI increases

      7/1/25 5:05:00 PM ET
      $ACOG
    • Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

      Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is

      5/15/25 8:30:00 AM ET
      $ACOG

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Havens John Prentiss

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/29/25 4:41:09 PM ET
      $ACOG
    • SEC Form 4 filed by Director Wills Robert James

      4 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:44:29 PM ET
      $ACOG
    • SEC Form 3 filed by new insider Wills Robert James

      3 - Alpha Cognition Inc. (0001655923) (Issuer)

      4/9/25 9:24:20 PM ET
      $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

      H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

      3/18/25 7:48:36 AM ET
      $ACOG

    $ACOG
    SEC Filings

    See more
    • SEC Form EFFECT filed by Alpha Cognition Inc.

      EFFECT - Alpha Cognition Inc. (0001655923) (Filer)

      7/9/25 12:15:09 AM ET
      $ACOG
    • SEC Form S-3 filed by Alpha Cognition Inc.

      S-3 - Alpha Cognition Inc. (0001655923) (Filer)

      7/1/25 4:29:08 PM ET
      $ACOG
    • Alpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alpha Cognition Inc. (0001655923) (Filer)

      6/23/25 5:00:33 PM ET
      $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

      1/14/25 8:30:00 AM ET
      $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    See more
    • Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

      Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is

      5/15/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

      Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

      5/1/25 8:30:00 AM ET
      $ACOG
    • Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

       Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

      3/31/25 8:30:00 AM ET
      $ACOG